| abstract |
This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, D2-like and 5-HT2 receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders incl. schizophrenia. Formula (I) an enantiomer thereof or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, or an N-oxide thereof. |